T1-A
Chambers, sessional
Grand Canal Capital Partners
Internal · 2026-05-09
Investment Intelligence Platform
Irish Dermatology — a structural undersupply,
institutionally addressable.
A 5-year, capital-efficient platform play to capture the structural undersupply of private dermatology services in Ireland through 2–3 consultant-led centres across Dublin, Cork, Waterford, and Galway.
€60–90m
GCCP-addressable
SOM at maturity
SOM at maturity
60,000+
Public OPD
waiting list
waiting list
47 / 82
Consultants vs.
ISF benchmark
ISF benchmark
8–12×
EBITDA exit
multiple range
multiple range
Source-of-truth: GCCP Dermatology MASTER repo
v0.1 · Living document
01 · Investment Thesis
Ireland is operating at less than half the dermatology supply ratio it requires.AI-DRAFT
The gap is not closing — it is widening. Demand grew 55% from 2019–2024; supply grew only 28%. The capacity deficit is the private sector.
Active consultants
47vs. ISF 82
Ireland operates at <58% of benchmark ratio
Public waiting list
60k+ patients
Some patients waiting up to 3 years
Private waits
12–24months
Insured patients at Blackrock, Mater Private
Single-clinic proof
€10–14m
Ryan/Ralph Institute revenue at ~40k visits
The five-line thesis
A structurally undersupplied private dermatology market, a binding consultant-supply constraint that favours organised platforms over solo practitioners, a precedent-setting single-clinic operator (the Institute of Dermatologists), an exit pathway validated by UK/EU comparables at 8–12× EBITDA, and a regulatory window that closes for disciplined operators within 18–30 months.
Why GCCP can win
- We can fund and build medical-grade real estate; this is core competence.
- We can structure PropCo/OpCo and align consultants through equity — analogous to our hotel operator model.
- We have LP relationships across the GCCP family-office matrix; healthcare appetite exists in the universe.
- Ryan/Ralph have proven the Dublin general/cosmetic model works. We replicate the format in regional cities where they are not present, and only enter Dublin on a differentiated sub-specialty axis.
What this is not
- Not a Dublin head-on play against Ryan/Ralph (suicide).
- Not a discount or volume-led model (kills clinical credibility and recapitalisation valuation).
- Not a build-everywhere-fast platform (capital efficiency over speed).
- Not a partner-proximity-driven default to Cork — site selection is data-led across the four cities.
Success definition · 5 years
Two or three dermatology centres operating to the Ryan/Ralph standard across the four target cities, generating recurring AM and equity carry, with a defensible clinical brand and a Phase 2 surgical centre opportunity in development. Platform is recapitalisation-attractive to UK/EU dermatology platform or healthcare PE.
02 · The Proven Model — Institute of Dermatologists
A 6-year-old, founder-led platform compounding from 2,900 sq ft to 40,000 patient visits per year.
IoD is the closest institutional template GCCP has. Their Phase 2 — Surgical Institute Dublin — opens June 2026 and is the timing window that frames the GCCP thesis.
Patient visits / yr
~40k
Confirmed by co-founders, Feb 2026
Estimated revenue
€10–14m
FY26 run-rate
EBITDA margin
25–35%
Estimated, sector-benchmarked
Footprint
~2,900sq ft
10 Pembroke Place, Ballsbridge D4
The model decoded
The Institute runs three distinct revenue streams under one roof — medical dermatology (GP-referred, insurer-billed), a full cosmetic suite (laser, injectables, PRP, microneedling, Ultherapy, body contouring), and a retail skincare product line. ID Formulas — a longevity skincare supplement brand — is the fourth revenue stream, built on the back of clinical brand credibility.
The quality differentiator
All botulinum toxin and dermal filler injections are performed by consultant dermatologists and plastic surgeons only. This is the positioning lever that justifies premium pricing and protects against regulatory risk from unqualified aesthetics practitioners. Credential transparency is the moat against Therapie/Sisu/Sk:n-style chains.
Founder profile · Caitríona Ryan
| Medical degree | UCD — first-class honours, first place in medical class |
|---|---|
| Specialist registrar | St Vincent's University Hospital, Dublin (Dermatology SpR) |
| Residency | Baylor Dermatology Residency Program, Dallas, Texas |
| Faculty post (US) | Vice Chair, Department of Dermatology, Baylor University Medical Center |
| Current academic | Associate Clinical Professor, UCD · Charles Institute of Dermatology |
| Boards | FAAD · FRCPI · International Psoriasis Council · BAD · IAD · BCDG |
| Publications | 70+ peer-reviewed papers (incl. JAMA, Lancet first-author) · Co-edited textbook Psoriasis 2nd ed. (Routledge) |
| Awards | IMAGE PwC Businesswoman of the Year 2025 — Entrepreneur of the Year |
| Media | Pat Kenny Show · Irish Times · IMAGE · own podcast (Dermatology S.O.S.) · 120k Instagram |
The IoD consultant team
| Consultant | Sub-specialty | Other affiliations |
|---|---|---|
| Prof. Caitríona Ryan (co-founder) | Medical & cosmetic, psoriasis, biologics, skin cancer | Blackrock Clinic; UCD Charles Institute |
| Prof. Nicola Ralph (co-founder) | Medical & surgical derm; photodermatology | Mater MUH (runs National Photobiology Unit); Blackrock Health |
| Prof. Eleanor Higgins | Medical & cosmetic — acne, rosacea, eczema, psoriasis | Blackrock Clinic; ex-St John's Institute London; UCD |
| Dr Isabel Haugh | Cosmetic, medical & paediatric (only paeds specialist in team) | Northwestern Feinberg + UT Southwestern fellowships; 400+ citations |
| + ~10 additional consultants | Surgical, Mohs (incoming), connective tissue, hair loss, oculoplastic | Cross-listed at SVUH, Mater Private, Beacon |
Surgical Institute Dublin — IoD Phase 2 (June 2026)
A dedicated Skin and Mohs Surgical Centre opening adjacent to the current clinic. Houses 20+ dermatologists, plastic surgeons, and oculoplastic surgeons working collaboratively under one roof. Built using a physician-investor model with Conor Murphy (also co-founder of ID Formulas) as commercial CEO — Ryan and Ralph lead clinical direction.
"Until recently, only one doctor performed Mohs surgery publicly in Ireland — at St James's, with public patients waiting nine months or more. Bon Secours Cork is the only private Mohs department in the country. The Surgical Institute Dublin is the first standalone private Mohs centre in Dublin."
Ryan / Ralph Competitor Intelligence · Reference Memo
Five lessons GCCP takes from IoD
- Clinical founder + commercial operator as co-founders — Ryan/Ralph (clinical) + Conor Murphy (commercial). This is the structure to replicate.
- Self-funded growth is possible — IoD invested €1.6m in expanded centre of excellence from operating cashflow within ~3 years.
- Consultants don't need to leave hospital posts — Ryan and Ralph remain at Mater / Blackrock alongside running IoD. GCCP's pitch is "build a private practice base alongside" — not "leave your hospital."
- The clinical brand is the moat; ancillary revenue compounds on top — ID Formulas, Surgical Institute, education / training all stack on the IoD halo.
- Don't compete with IoD in Dublin head-on — go where they aren't going: Cork, Galway, regional flagships, sub-specialty differentiation in Dublin only.
03 · National Market Sizing
A €550–700m total economy. A €280–400m private pool. A €60–90m GCCP shot.
Triangulated bottom-up from NCRI, NTPF, HSE, Statista, Euromonitor, and operator-level disclosures. UK per-capita cross-check passes.
Irish dermatology economy — TAM decomposition
FY26 estimate · €m · midpoints
Bottom-up market table
| Metric | FY26 estimate | 5-yr CAGR | Confidence |
|---|---|---|---|
| Total Irish dermatology TAM (services + retail) | €550–700m | 6–8% | Medium |
| Public / HSE spend (incl. biologics, phototherapy, OPD) | €150–200m | 4–5% | High |
| Private dermatology services SAM | €280–400m | 8–10% | Medium |
| GCCP-addressable SOM (multi-specialty centres) | €60–90m | — | Target |
| Adjacent retail (skincare, cosmeceuticals, trials, education) | €280–320m | 9–11% | Medium |
Source: GCCP Strategy bottom-up roll-up · NCRI · NTPF · HSE NSP · Statista · Euromonitor · operator disclosures.
Three takeaways for the platform thesis
The whitest white-space
Skin-cancer screening + surgical dermatology — €20–35m private pool, ~12% CAGR, only one private Mohs centre in Ireland (Bon Secours Cork). GCCP's sharpest entry vector.
The load-bearing wall
Medical dermatology is the most defensible anchor: €70–95m private pool, sticky biologics-eligible cohorts, insurance-reimbursed, low cosmetic-cyclicality. IoD proves €10–14m at 40k visits.
The cash-flow engine
Cosmetic injectables + laser is the largest pool (€170–250m) but the most contested. A consultant-led "medical-grade" position is differentiable; a chain race-to-the-bottom is not.
04 · Supply & Demand Gap
Demand is growing twice as fast as supply.
Per the HIQA April 2026 Health Technology Assessment — the canonical document on the state of Irish dermatology — demand grew 55% from 2019–2024 while WTE consultant supply grew only 28%.
Demand-supply divergence · Irish dermatology · 2019–2025
indexed to 2019 = 100
| Metric | Figure | Date | Source |
|---|---|---|---|
| Patients waiting for consultant dermatologist OPD | >60,000 | Jun 2025 | HIQA HTA Apr 2026 |
| Annual new referrals from primary care | 99,994 | 2024 | HIQA HTA |
| Growth in referrals 2019–2024 | +55% | — | HIQA HTA |
| Growth in WTE consultant supply 2019–2025 | +28% | — | HIQA HTA |
| Patients waiting >12 months | >10,000 | 2023 | AllView / Pharmacy News IE |
| Some patients waiting | up to 3 years | 2025 | HIQA Chief Scientist |
| Completed public OPD appointments per year | ~150,000 | 2024 | HIQA HTA |
| Public ISF benchmark shortfall | ~22% | Apr 2025 | ISF · NCPD |
"There remains an urgent need to recruit more consultant dermatologists."
HIQA Chief Scientist · March 2026
The POCC23 wedge
The Public Only Consultant Contract (effective January 2026) prohibits new POCC23 holders from on-site private practice in public hospitals — 60% of HSE consultants are now on POCC. This systematically channels private caseload into purely private facilities. A decade-long structural tailwind, not a cyclical one.
05 · The Consultant Universe
~80 active consultant dermatologists across the island. The recruitment universe is named, mapped, and reconciled.
Two independent long-list pulls (Perplexity Pro · ChatGPT v2) reconciled to a working universe of 78–85 active practitioners. ~46 in Dublin · ~14 in Cork · ~3 in Galway · ~4 in Limerick/Clare · 2 in Waterford · 12 counties with zero listed.
Active in Ireland
75–95
IMC Specialist Register · active practice
CCT graduates / yr
3–4
~6–8 needed to stand still
HST training posts (RoI)
17
+ 8 in NI · 5-yr programme
Diaspora pool
8–15
UK · AU · US · UAE returner-eligible
Geographic distribution
| City / region | Active consultants | Density per 100k | vs. benchmark (1.0/100k) |
|---|---|---|---|
| Dublin metro (incl. Tallaght, Blackrock) | ~46 | 1.10 | Below benchmark |
| Cork | ~14–15 | 0.51 | Half benchmark |
| Galway | ~3 | 0.36 | ⅓ benchmark |
| Limerick / Clare | ~4 | 0.49 | Half benchmark |
| Waterford | 2 | ~0.5 | Below |
| Kerry | 2–3 | ~0.4 | Below |
| Sligo | 1 | ~0.5 | Below |
| Louth (Drogheda) | 1–2 | ~0.5 | Below |
| Kildare | 1–2 | ~0.5 | Below |
| Belfast / NI | 9–10 | ~0.5 | Below |
| Wexford · Kilkenny · Carlow · Laois · Offaly · Wicklow · Meath · Tipperary | 0 | 0 | ZERO LISTED |
Source: Reconciled long-list — 02_Clinical_Partner_Track/long_list_reconciliation.md · IAD Find-a-Dermatologist register · IMC Specialist Division
The setting split
| Setting | Estimated # | Notes |
|---|---|---|
| HSE primary post (with private off-site rights, legacy contracts) | 55–65 | Type B / C — primary recruitment universe |
| Private-only / predominantly private | 15–25 | IoD, Blackrock Health, Beacon, Bon Secours, Hermitage, regional clinics |
| Recently-returned international / visiting clinical professors | 5–10 | Diaspora signal · Cleveland Clinic / Baylor / NHS / AU |
| Total active | ~75–95 | IMC verification pending |
Recent capacity formation
Time-stamped events that materially change the consultant supply picture:
| Date | Event | Net effect |
|---|---|---|
| Jun 2023 | Aoife Lally's private practice at SVPH closed | Dublin private –1 |
| Jul 2023 | Stephanie Menzies CCT'd; visible across Beacon and IoD | Dublin private +1 |
| Jul 2024 | Kate Lawlor CCT'd; Bon Secours Tralee profile + South Wales appointment | Status unclear · Tralee/Wales |
| 2025 | Niamh Byrne built Dublin private practice at Blackrock — Cambridge-trained, medical + surgical | Dublin private +1 net (premium positioning) |
| 2025 | Dr Isabel Haugh founded Dr Haugh Dermatology & Aesthetics, Adelaide Rd D2 | New Dublin competitor — paediatric & cosmetic |
| Mar 2025 | Lisa Roche re-joined SIVUH (Cork) in permanent consultant role | Cork public +1 |
| Feb 2026 | Cathal O'Connor appointed locum at CUH (London fellowship in genodermatoses + paediatric) | Cork +1 · only post-fellowship paediatric outside Dublin |
Strategically interesting recruitment targets
Cathal O'Connor (Cork, post-London fellowship) and Niamh Byrne (Dublin, Cambridge-trained) are the most strategically interesting net additions. Both Irish-trained, both fresh fellowships, both early-career private positioning. Realistic Stage 2 outreach targets if platform positioning aligns with their sub-specialty.
Recruitment market signals
- Type B / C contract holders are the priority pool. Already split between HSE and private; can be offered rooms-and-platform deal or partner equity without forcing them to leave the HSE.
- Mid-career exits from public posts: anecdotal evidence of frustration with HSE administrative burden, slow consultant-post approvals (IHCA: 142 of 309 vacancies unfilled >12 months), and capped on-site private activity. Several reportedly evaluating private-only.
- Diaspora returners: 8–15 Irish consultants in UK / AU / US / UAE. Returners typically seek (a) equity, (b) lifestyle, (c) school-age family pull. Run structured outreach Q3 2026.
- UK consultants seeking IMC Specialist Division registration: small but growing, especially post-Brexit private-pay friction in London. ~6–12 month registration timeline.
Sourcing channels
- Direct approach via personal network (Ryan, Ralph, IoD alumni, RCPI alumni)
- Targeted LinkedIn outreach (search yields ~60–80 individuals)
- RCPI dermatology trainee committee (Y4–Y5 SpRs approaching CCT)
- Industry-specific recruiters (Global Medics, CSEConnect, Locum Direct)
- UK / AU / US "return to Ireland" career fairs (RCPI hosts annually)
06 · Consultant Economics
Public scale tops at €280k. Private earnings clear €500k. Equity-partner anchors push €900k+.
Total clinical compensation envelope at platform scale (Y5) is estimated at €7.0–8.5m per annum platform-wide — 55–65% consultant draw, 35–45% allied health.
Public scale (HSE 2025/26 POCC pay)
The 2023 Public-Only Contract sets a 6-point scale: €209,915 → €252,150 rising to €280,513 at the top of the post-2025 increased scale (PSA 2024–2026 1% August 2025 uplift; February 2026 adjustments). Add allowances:
- On-call / clinical director / academic uplifts: €10–40k
- Pension (defined-benefit, Single Public Service Pension Scheme for new entrants)
- 30 days annual leave + 11 days study leave
Effective public consultant total package: ~€230k–€310k including allowances and pension value, before any private earnings.
Private earnings benchmarks
| Engagement model | Headline rate | Notes |
|---|---|---|
| Sessional (per 4-hour clinic) | €1,000–€1,800 / session | Self-employed, room+secretarial included; consultant retains receipts less platform fee |
| % of receipts (associate model) | 60–75% to consultant | Industry standard at IoD-style centres; varies with cosmetic vs. medical mix |
| Cosmetic procedural (Botox / filler / laser) | ~70–85% to consultant | Higher because product cost borne by clinic |
| Mohs / surgical day rate | €2,500–€4,000 / day | + procedural fees · supply-constrained specialism |
Indicative private earnings ramp · full-time, mature book
| Stage | Annual earnings |
|---|---|
| Year 1 ramp | €180k–€280k |
| Year 2–3 stabilised | €350k–€500k |
| Mature anchor consultant | €500k–€900k+ |
Total comp by model
| Model | Total comp range | GCCP fit |
|---|---|---|
| Hybrid (HSE base + 2 private days) | €280k–€450k | Sessional contractor in our centre |
| Full-private associate (no HSE) | €350k–€650k | Salaried / % deal, no equity |
| Full-private partner (with platform equity) | €450k–€900k cash + capital event | GCCP target for anchors |
UK comparator
NHS consultant scale 2025: ~£105k–£141k base + Clinical Excellence Awards. Private NHS consultants typically add £150k–£500k+ private. Top London cosmetic dermatologists at sk:n / Cadogan / Harley Street can clear £700k–£1.5m+ all-in. Ireland trades ~10–20% below London for equivalent volume — but with materially lower competition and much shorter waiting lists (a marketing tailwind).
07 · Equity Architecture
Four reference archetypes. One recommended GCCP structure.
Ireland is small enough that 2–3 anchor consultants effectively are the platform. Equity, non-compete, and operational structures must mitigate that key-person exposure.
The four archetypes
7a · Institute of Dermatologists (Dublin)
Model: Consultant-founded centre of excellence combining medical, cosmetic, surgical, skincare. ~14-strong faculty, ~40k patients/year. Co-founders (Ryan, Ralph) hold equity; associates likely on % of receipts.
Lesson: The bullseye comparator. Multi-consultant, partnership-led, US-style centre-of-excellence. Platform value sits with the founders.
7b · sk:n Group (UK · TriSpan PE)
Model: ~70+ clinics, 150+ doctors/consultants, 800 employees. PE-owned platform; consultants employed or contracted, not equity partners. Brand is the asset.
Lesson: The late-stage model. At 2–3 centres GCCP cannot run sk:n economics. Consultants need to feel like owners. Sk:n collapsed July 2024.
7c · Cadogan Clinic (London)
Model: 100+ GMC consultants, multidisciplinary, founder-led. Six consulting rooms + five operating rooms. Consultants self-employed, paying for rooms / theatre time — "platform-as-a-service."
Lesson: Useful flagship template for Dublin 8,000 sqft. Lighter equity but sticky because the infrastructure is hard to replicate.
7d · Schweiger Dermatology (US · LNK Partners)
Model: Roll-up of physician-owned practices. Selling physicians retain equity, receive cash event, continue practising. ~$488m raised; founder still CEO.
Lesson: The "buy-and-roll" model relevant when GCCP hits Y3–Y5 and starts acquiring sub-scale Irish practices.
The recommended GCCP architecture
| Tier | Who | Structure | Equity envelope |
|---|---|---|---|
| Tier 1 · Founding Partners | 2–4 anchor consultants | 5–10% each in OpCo (or HoldCo above OpCo + PropCo) · 4-yr vest, 12-mo cliff, leaver provisions · "eat what you kill" pay (% of receipts) + pro-rata share of platform EBITDA | 10–40% total |
| Tier 2 · Associate Consultants | 4–8 across centres | % of receipts model · no equity at hire · option pool vesting with tenure / performance · non-compete radius (~5–10km, 12 months post-departure) | 5–10% option pool |
| Allied health / non-clinical leadership | Practice managers, RANP leads, marketing | Phantom equity / EBITDA bonus pool | 5–10% |
| Total partner / option envelope | 20–35% of OpCo | ||
Leaving 65–80% to GCCP / LP capital. In line with what private platforms in Ireland will need to give away to anchor genuine clinical talent.
PropCo / OpCo structure
GCCP's preferred wrapper: PropCo holds the building (60–70% GCCP ownership; lets to OpCo on triple-net basis at market rent); OpCo holds the operating clinic (consultant equity sits here, not in PropCo). Triple-net lease aligns clinical performance with property cashflow without dragging GCCP into clinical operations. Mirrors the GCCP hotel operator model.
08 · Allied Health & Staffing Model
A scaled centre is 80% allied-health by headcount. The economics work only if the consultant is the highest-priced clinician.
RANPs, Mohs technicians, and dermatology medical photographers are the three critical scarcity points — likely require active poaching from CHI / Beaumont / SVUH or UK recruitment.
Allied-health roles · supply, comp, training
| Role | IE supply | Training route | Annual comp |
|---|---|---|---|
| Registered Advanced Nurse Practitioner (RANP) — Dermatology | Very scarce — single-figure RANPs nationally | RGN → MSc Advanced Practice (UCC, Galway, TCD) + 500 supervised hrs + NMBI registration | €75–110k base + on-call |
| Clinical Nurse Specialist (CNS) — Dermatology | Modest pool, mostly hospital-employed | RGN + dermatology-specific post-grad; NMBI division | €60–80k |
| Aesthetic / Dermatology Nurse | DANAI-affiliated; growing | RGN + private aesthetics training | €45–65k base + commission |
| Medical Photographer | Very scarce — most are NHS-trained UK | IMI / clinical photography qualifications | €45–55k |
| Mohs Histotechnologist | Almost none private-side; HSE-trained | On-job + IBMS or US-trained | €55–75k |
| Aesthetician / Skin Therapist | Plentiful | CIDESCO / ITEC | €30–45k + commission |
| Patient Coordinator / Reception | Plentiful | None specific | €30–40k |
| Practice Manager (Centre) | Modest | Healthcare ops background | €70–90k |
Per-centre staffing — flagship Dublin (~8,000 sq ft)
6 consulting rooms, 2 procedure rooms, 1 minor-op theatre.
| Role | FTE | Rationale |
|---|---|---|
| Lead Consultant Dermatologist (anchor / founding partner) | 1.0 | Brand anchor, MDT lead, recruitment magnet |
| Associate Consultants | 3–4 | Cover medical, cosmetic, surgical / Mohs, paediatric |
| Visiting / Sessional Consultants | 0.5 | Sub-specialty coverage |
| Registered ANP (Dermatology) | 2 | Triage, reviews, biologics monitoring |
| Clinical Nurse Specialists | 2 | Phototherapy, paediatric eczema, biologics |
| Aesthetic Nurses | 2 | Cosmetic procedural list |
| Medical Photographer | 1 | Mole-mapping, surgical doc, marketing assets |
| Mohs Tech | 1 | Required if Mohs in scope |
| Aestheticians / Therapists | 3 | Skincare and lower-acuity revenue |
| Practice Manager | 1 | Centre P&L, operator interface |
| Patient Coordinators / Reception | 4 | Bookings, billing, insurer reconciliation |
| Marketing / Front-of-house Lead | 1 | Brand, content, cosmetic concierge |
| Total | ~21–24 FTE | Allied health is 80% of headcount |
Per-centre staffing — satellite (~4,000 sq ft)
| Role | FTE |
|---|---|
| Lead Consultant + 1 Associate | 2.0 |
| Visiting Consultants | 0.5 |
| RANP | 1 |
| Aesthetic Nurse + CNS | 2 |
| Aestheticians | 1.5 |
| Practice Manager / Reception / Coordinator | 3 |
| Total | ~10 FTE |
09 · Geographic Opportunity
Outside Dublin, private dermatology supply is genuinely thin.
Stage 1 scope locked to four cities. Site selection is data-led, not partner-proximity-led — Cork is no longer presumed Clinic 1.
| City | Catchment | Private supply today | GCCP working hypothesis | Stage |
|---|---|---|---|---|
| Dublin | 5.2m region | 16 listed private; Ryan/Ralph dominant | Differentiated sub-specialty only — never head-to-head with IoD. Hatch Street as possible pilot. | Stage 1 |
| Cork | ~580k city-region | 3 listed; Bon Secours Mohs, Lee Clinic, Cork Dermatology, Carrigtwohill | Strong narrative (Half Moon Street relationship; thin private supply). Must compete on evidence — no longer presumed Clinic 1. | Stage 1 |
| Waterford | ~120k county | 0 listed | South-East catchment. Open question: standalone vs satellite/visiting-consultant model from Cork or Dublin. | Stage 1 |
| Galway | Connacht catchment | 1 listed; Bon Secours + Galway Clinic present | High-income demographic. Saturation vs. under-served question to resolve. | Stage 1 |
| Limerick | — | 1 listed | Deferred unless surfacing data brings forward. | Phase 2 |
| Belfast | — | 9–10 listed | Cross-border / NI regulatory complexity outside Stage 1 scope. | Phase 2 |
The single sharpest geographic fact
Waterford / Wexford / Kilkenny / Carlow / Laois / Offaly / Kildare / Wicklow / Meath / Tipperary / Clare / Kerry — zero private consultants listed across twelve counties. The supply gap outside the four major cities is acute.
Consultant density per 100k · benchmark vs. actual
County-level consultant density
vs. Comhairle 1-per-100k benchmark
10 · Sub-Sector Decomposition
Fifteen sub-sectors. Three anchors. One race-to-the-bottom to avoid.
The dermatology service universe mapped by scale, saturation, opportunity, margin, and GCCP fit. Sources: GCCP sub-sector primer + market sizing roll-up.
| Sub-sector | IE €m | CAGR | Saturation | Opportunity | EBITDA | GCCP fit |
|---|---|---|---|---|---|---|
| Mohs / surgical dermatology | €15–22m | 10–12% | Critical undersupply | 5/5 | 25–35% | Anchor 1 |
| Medical dermatology | €70–95m | 7–9% | Medium | 5/5 | 25–35% | Anchor 2 |
| Skin cancer screening / mole mapping | €8–14m | 11–13% | Low | 5/5 | 30–40% | Anchor 3 |
| Cosmetic / consultant-led (Tier A) | €120–170m | 9–12% | Low at Tier A | High | 25–40% | Margin layer |
| Laser & light-based | €50–80m | 8–10% | Medium | Medium | 20–30% | Stack |
| Biologics / advanced systemic therapy | €10–20m+ | 12–15% | Very low (private) | High | 25–35% | Stage 1 |
| Phototherapy / PDT | €2–5m | 4–6% | Very low (private) | Medium-High | 25–35% | M/L scenario |
| Patch testing / contact | €3–7m | 5–7% | Low | Medium | 25–35% | Bundle |
| Teledermatology | €2–5m | 20–25% | High (AllView) | Medium | 15–25% | Partner |
| Trichology / hair restoration | €15–25m | 9–11% | Low-Medium | Medium-High | 25–45% | Stage 2 |
| Paediatric dermatology | €5–9m | 6–8% | Low | Medium | 15–25% | Stage 2 |
| Occupational dermatology | €8–15m | 6–8% | Low | Medium | 25–35% | B2B wedge |
| Cosmetic-only (Tier D — Therapie/Sisu) | €120–170m | 9–12% | Very high | 1/5 | 15–25% | AVOID |
| Skincare retail / DTC | €10–20m | 10–13% | Low at consultant tier | Brand layer | 15–25% | Stage 3+ |
| Vulval & genital dermatology | Niche | — | Very low | Credibility | 25–35% | Bundle |
Source: 09_Reference/02_Dermatology_Sub_Sector_Primer.md · research/02_market_sizing_subsectors.md
11 · White-Space Map
The institutional, multi-specialty, consultant-led centre is a white-space of one in Ireland today.
With IoD's Surgical Institute opening June 2026, the market is moving from a zero to a one. GCCP's window to be the second-and-third institutional centre is open today and likely closes within 18–30 months.
| Sub-sector | Demand intensity | Current supply | White-space |
|---|---|---|---|
| Mohs micrographic surgery | High (>13k NMSC/yr) | 1 private centre (Bon Secours) + St James's public | 5/5 — RED HOT |
| Multi-specialty institutional centres | High | IoD only (and IoD Surgical Institute opens June '26) | 5/5 — GCCP THESIS |
| Total-body AI-assisted mole mapping | High and rising | 3–4 dedicated private clinics | 4/5 |
| Consultant-led teledermatology (premium tier) | High (HSE waitlist 60k+) | 1–2 active operators (DermView, Vhi360) | 4/5 |
| HS / autoimmune sub-specialty private clinic | Moderate (1% prevalence ~54k pts) | Effectively zero dedicated private | 4/5 |
| Paediatric atopic dermatitis private centre | High (15% childhood AD) | None at scale (CHI dominates public) | 3/5 |
12 · Operator Landscape
40+ private dermatology operators across the island. Three competitive registers.
The market bifurcates: institutional consultant-led centres at the top (IoD, Blackrock, Mater Private, Belfast Skin); volume cosmetic chains at the bottom (Therapie, Sisu, the now-defunct Sk:n); and a wide middle of solo / small-group consultant practices. Source: research/03_competitive_landscape_ireland.md.
Geographic capacity heat-map · sub-sector × city
| Region | Medical Derm | Surgical / Mohs | Cosmetic | Paediatric | Capacity grade |
|---|---|---|---|---|---|
| Dublin (D2/D4) | Heavy — IoD, Beacon, Mater Private, SVPH, Blackrock | Strong — Ormond, Murad, Coleman, Adare | Heavy & crowded — Ailesbury, Adare, BFD, Eden, River Medical, Renaissance, Sk:n legacy | Thin — covered ad-hoc by Beacon, OLCHC consultants in private rooms | A− |
| Dublin (West / Hermitage) | Light | Light | Light | None | C |
| Cork | Moderate — Bon Secours, Lee Clinic, Mater Private Cork, UPMC Cork | Moderate — Lee Clinic Mohs, Bon Secours | Crowded (Therapie, River, Ailesbury Cork) | Lee Clinic offers paeds | B |
| Galway | Moderate — Galway Clinic, Bon Secours, Blackrock Health | Light | Moderate (Galway Skin, Kelly Clinic) | None notable | C+ |
| Limerick | Light — Bon Secours, Blackrock Health | Very light | Light | None | C |
| Waterford | Light — UPMC Whitfield (Rose Clinic) | Light | Very light | None | D |
| Belfast | Strong — Belfast Skin, Kingsbridge, Cathedral, Ulster Independent, Claro | Strong — Mohs at Belfast Skin, Kerr at Kingsbridge | Strong | Belfast Skin notable for paeds | B+ |
| Derry / NW | Light — Kingsbridge North West | Very light | Light | None | D |
| Kilkenny / Carlow / Wexford | Visiting clinics only | None notable | Light | None | D |
Strategic read
The medical and paediatric dermatology white-space is in Dublin's western/southern fringe, in Limerick, in Waterford, and outside the M50 generally. Cosmetic is saturated in Dublin and Cork — entering on cosmetic alone is a price-war strategy.
Tier-1 institutional operators · master table
Operators of scale, with at least one IMC-registered specialist consultant dermatologist on staff. Revenue and EBITDA are estimates per research/03 methodology unless a CRO/Companies House figure is cited.
| Name | City | Lead consultant(s) | FTE | Rev €m [est.] | EBITDA% [est.] | Notes |
|---|---|---|---|---|---|---|
| Institute of Dermatologists | Dublin (Pembroke Pl, D4) | Ryan, Ralph, Higgins, Verma | 5–6 | 7–9 | 25–32% | ANCHOR BENCHMARK |
| Blackrock Clinic — Dermatology | Dublin (Blackrock) | Ryan, Higgins, Coleman, Ormond, Salim, Condon | 6–8 | 6–8 | n/m (hospital) | Single largest concentration of senior derm consultants in ROI |
| Mater Private Dermatology | Dublin (Eccles St) | Murad, Keane, Storan + visiting | 4–5 | 3–4 | n/m | Skin-cancer / Mohs strength · InfraVia portfolio |
| Beacon Hospital — Derm Dept | Dublin (Sandyford) | Ahmadi + 2 visiting | 3 | 3–4 | n/m | Hospital outpatient model |
| St Vincent's Private — Derm | Dublin (Elm Park) | A. Ryan + 4 others | 5 | 2.5–3.5 | n/m | Charitable; public-private hybrid |
| Restorative Dermatology (Coleman) | Dublin (within Blackrock) | Rosemary Coleman | 1 | 1.4–1.8 | 30–38% | High-margin solo · own skincare line |
| Adare Clinic | Dublin (Clare St D2) | Multi-consultant + nurses | 2–3 | 2–3 | 18–24% | Hybrid medical-cosmetic; multi-site |
| Ailesbury Clinic | Dublin (Clonskeagh D4) | Treacy, de Klerk, Divya | 3–4 | 4–6 | 15–22% | Strongest cosmetic-derm brand · Cork sister site |
| Beacon Face & Dermatology (BFD) | Dublin (Beacon) | Patrick Treacy & team | 1.5 | 1.5–2.5 | 18–24% | Cosmetic-heavy |
| Skin & Hair Clinic (Murad) | Dublin (Eccles St) | Aizuri Murad | 1 | 1.0–1.5 | 28–35% | Murad's own private rooms · platform-anchor candidate |
| Dr Haugh Dermatology | Dublin (Adelaide Rd D2) | Isabel Haugh | 1 | recent (2025) | est. 30%+ | New competitor · paediatric & cosmetic |
| Eleanor Higgins Cosmetic Derm | Dublin (within IoD/Blackrock) | Higgins | 1 | 0.8–1.2 | 32–40% | Personal brand; high-margin solo |
| Hermitage Medical — Derm | Dublin (Lucan) | Visiting (rota) | 1.5 | 1.0–1.5 | n/m | Underweight on derm vs other Blackrock Health sites · West Dublin whitespace |
| Bon Secours Cork — Derm | Cork (College Rd) | Molloy, Fahy + visiting · Mohs (only private in IE) | 3 | 2–3 | n/m | Largest Cork private derm hub · Mohs anchor |
| Lee Clinic Dermatology | Cork (Lee Rd) | O'Connor, Gibson + others | 3–4 | 2.5–3.5 | 28–34% | HIGHEST-QUALITY ACQUISITION TARGET · Mohs + paediatric |
| Mater Private Cork — Derm | Cork | Sally O'Shea + others | 2 | 1.0–1.5 | n/m | Smaller but growing footprint |
| Galway Clinic — Derm | Galway (Doughiska) | Markham, Shaikh + visiting | 2–3 | 1.5–2.5 | n/m | Hospital-resident dermatologists |
| Perfect Skin (Shaikh) | Galway (within Galway Clinic) | Taj Shaikh | 1 | 0.9–1.3 | 30–38% | Acquisition target candidate |
| UPMC Whitfield (Rose Clinic) | Waterford (Cork Rd) | Visiting consultants | 1 | 0.8–1.3 | n/m | Single private hospital in SE region |
| Belfast Skin Clinic | Belfast (Lisburn Rd) | Multiple — derm, plastics, allergy, paeds | 4–6 | 4–6 | 22–30% | BEST NI MEDICAL-DERM CLINIC · partnership candidate |
| Cathedral Dermatology | Belfast | Consultant derm + plastic surgeons | 2–3 | 1.0–1.6 | 24–30% | Consultant-led |
| Kingsbridge Private Hospital — Derm | Belfast + Sligo + NW | Murphy, Kerr (visiting), others | 3 | 2–3 | n/m | 3fivetwo Healthcare Group |
| Ulster Independent Clinic — Derm | Belfast (Stranmillis) | Kerr + visiting | 2–3 | 1.3–2.0 | n/m | Long-established consultant venue (1947) |
| Claro Skin Clinic | Belfast | Olga Kerr | 1 | 0.9–1.3 | 30–35% | Kerr is one of NI's few Mohs-trained dermatologists |
Volume cosmetic chains · adjacent, not direct competitors
| Name | Footprint | Model | Status / signal |
|---|---|---|---|
| Therapie Clinic | 30+ ROI sites · 100+ all-Ireland | Doctor + nurse network · no consultant derm · volume cosmetic | Group revenue €60–90m all-Ireland · 200k+ Instagram · partnership / referral candidate, not derm competitor |
| Sisu Clinic | 24–25 sites IE/UK/US | Digital-native aesthetic · doctor-led | $20.5m revenue · 47% YoY growth · VC-backed |
| Sk:n Clinics | — | — | CEASED TRADING JUL 2024 · TriSpan PE roll-up failure · cautionary tale |
| River Medical | Dublin / Cork / Belfast | Plastic surgery + aesthetics | €4–7m group rev · adjacent, not direct |
| The Skin Nurse | Dublin | Nurse prescriber-led | Award-winning · strong social |
| Eden Medical / ClearSkin / Refine / ORA / Amara / Glow / SkinGlow | Dublin (multiple) | Aesthetic / cosmetic doctor-led | ~€0.2–2.5m each · long tail |
Acquisition targets · ranked
- Lee Clinic Dermatology (Cork) — €2.5–3.5m revenue, 28–34% EBITDA, Mohs + paediatric capability. The single highest-quality independent private derm acquisition target in Ireland.
- Belfast Skin Clinic — €4–6m revenue, multi-specialty (derm + plastics + allergy + paeds), founder-led. Strongest NI partnership / acquisition opportunity. Cross-border patient flow already exists.
- Perfect Skin (Shaikh, Galway) — €0.9–1.3m solo specialist; could become a Galway anchor with operator support.
- Skin & Hair Clinic (Murad, Dublin) — Murad's own rooms; pre-cursor to potential platform anchor if recruited as Tier-1 founding partner.
13 · Pricing & Service Mix
Three price tiers operate. The opportunity is at the top with selected insurer rails.
Most consultant-led clinics do not publish transparent menus — pricing is verbal on enquiry or buried in FAQ pages. The aesthetic chains are the opposite: aggressive online price advertising. This bifurcation is the strategic opportunity for GCCP. Source: research/09_service_mix_pricing.md.
The three price tiers
| Tier | Positioning | Initial consult | Examples |
|---|---|---|---|
| Premium / Consultant-led | Specialist register dermatologist · Ballsbridge / D2 / D4 / Beacon Suite · low patient volume · high price | €250–€500 | Institute of Dermatologists, HRBR, Beacon Face & Dermatology, Dr Haugh, Dr Morrow |
| Hybrid / Hospital-private | Consultant-led inside private hospital · insurer rails · mid-volume | €180–€280 | Beacon Hospital, Mater Private, Blackrock Health, Hermitage, Galway Clinic, UPMC |
| Value / Aesthetic chain | Nurse / GP / cosmetic-doctor led · high volume · retail format | €0–€149 (often free consult) | Sk:n (defunct), Thérapie, Sisu, Laser + Skin Clinics |
GCCP positioning recommendation
Premium with selected insurer rails — an Institute-of-Dermatologists-class medical brand at the top of the funnel, with a deliberately curated cosmetic and skincare wing that picks off Beacon-style hybrid revenue without diluting the brand. Higher capex / higher fit-out / higher EBITDA-margin model than a Sk:n-style chain — and more defensible against consolidator entry.
Headline economics · modelled
| Metric | Premium | Hybrid |
|---|---|---|
| Blended revenue per consultant 4-hour session | €1,950–€2,650 | €1,250–€1,650 |
| Revenue per consult room per day (10-hr window) | €2,800–€4,800 | €1,800–€3,000 |
| Revenue per consult room per year (220 trading days) | €620k–€1.05m | €395k–€660k |
| Revenue per sq ft (well-utilised, ~3,000 sq ft) | €2,000–€3,200 | €1,300–€2,000 |
Indicative pricing · core medical services
| Service | Range | Premium ceiling |
|---|---|---|
| Consultant initial consultation (medical) | €250–€500 | €500 (HRBR senior) |
| Follow-up consultation | €150–€250 | €220 |
| Paediatric dermatology consultation | €250–€350 | €350 |
| Mole check / single spot | €70–€150 | €150 |
| Full-body skin cancer screening | €180–€300 | €300 |
| Mole mapping — FotoFinder ATBM full-body | €350–€495 | €495 (Molescan, River Medical) |
| Mole mapping — annual rescan (yr 2+) | €250–€325 | €325 |
| Skin biopsy — punch (incl. histology) | €120–€350 | €350 |
| Excisional surgery — benign / suspect lesion | €400–€1,400 | €1,400 (theatre + histology) |
| Mohs first stage | €1,400–€2,400 | €2,400 (Belfast Skin comparator) |
| Mohs additional stage | €600–€900 | — |
| Mohs reconstruction (per defect) | €800–€2,500 | — |
| Cryotherapy — first lesion | €80–€150 | €150 |
| Patch testing — full European baseline + extended | €350–€550 | €550 |
| Phototherapy UVB course (24 sessions) | €1,400–€1,900 | €1,900 |
| Photodynamic therapy (PDT) — face/scalp two-session protocol | €1,200–€1,800 | €1,800 |
| Biologics — clinic-led monitoring package (annual, 4 visits) | €600–€900 | €900 |
Indicative pricing · cosmetic / aesthetic
| Service | Volume chain | Premium consultant |
|---|---|---|
| Botox — 1 area | €149 (Thérapie women) | €300 (Ailesbury / IoD) |
| Botox — 3 areas | €350 | €450–€550 |
| Hyperhidrosis — both axillae (W) | €550–€650 | €600–€700 |
| Dermal filler — per ml | €295 (Thérapie) | €350–€550 |
| Tear-trough filler | — | €450–€650 (premium-only — high-skill) |
| Microneedling — single session | €180–€220 | €250–€295 |
| RF microneedling (Secret Pro / Morpheus8) | €700–€950 | €1,200–€1,500 |
| Chemical peel — superficial | €130–€195 | €150–€225 |
| Chemical peel — medium TCA 15–25% | €295–€395 | €395–€495 |
| Laser hair removal — face (course of 6) | €375–€450 | €595–€750 |
| Laser hair removal — full body (course of 6) | €1,250–€2,000 | €2,000–€2,800 |
| Vascular laser — course of 3 (rosacea) | €595–€795 | €995–€1,250 |
| Fractional CO₂ — full face | €1,500 | €1,800–€2,500 |
| Acne treatment package (3 months · consult + 3 peels + topical) | €595–€795 | €795–€995 |
Margin profile by service
- Highest gross margin: mole mapping (≈82%) · package memberships (≈75%) · aesthetic injectables (≈68%) · skincare retail (≈42% gross / 30% net of staff)
- Lowest gross margin: biologics admin (≈25% — drug pass-through is near-zero margin) · Mohs surgery (≈30% net of theatre/histology) · patch testing (≈40%)
VAT note: cosmetic procedures are 23% VAT-able; medical procedures (incl. biopsy, screening, cryotherapy of pre-cancerous lesions, consultant-billed medical care) are VAT-exempt.
14 · The 9-Cell Tier Matrix
Three tiers. Three divisions. Nine cells. One top-scored model.
Each cell scored across seven dimensions — profitability, scalability, capital efficiency, OpCo/PropCo capability, complexity inverse, founder-time inverse, and risk-adjusted return — totalling 100 points.
Division A · Medical
Division B · Cosmetic
Division C · Surgical / Skin Cancer
Tier 1
€100k–€1m
€100k–€1m
T1-B
Chambers + 1 device
T1-C
Screening only (no Mohs)
Tier 2
€500k–€4m
€500k–€4m
T2-A
Boutique medical-led
T2-B
Boutique cosmetic + medical
T2-C
Day-surgery + TBI (no Mohs)
Tier 3
€8m–€50m+
€8m–€50m+
T3-A
Multi-site GP-referrer
T3-B
Premium hub + chain
T3-C
Mohs flagship + biologics + paeds
Top three by total score
| Rank | Cell | Full name | Score | Capex | Y5 revenue | EBITDA | Y5 EV | EV/Capex |
|---|---|---|---|---|---|---|---|---|
| 1 | T2-B | Tier 2 Cosmetic Boutique with medical mix | 78.4 | €2.0m | €5.8m | €1.91m / 33% | €22m | 11.0× |
| 2 | T3-B | Tier 3 Cosmetic Premium Hub + Skin Clinics Chain | 78.2 | €15m | €22m | €7.7m / 35% | €92m | 6.1× |
| 3 | T2-A | Tier 2 Medical Boutique | 69.7 | €1.8m | €5.5m | €1.49m / 27% | €16m | 8.9× |
The headline finding
Cosmetic division (B) dominates the scoring across all three tiers. Cosmetic boutique single-clinic (T2-B) is the highest-scoring single cell — highest-margin cash-pay revenue, scalable, lighter regulatory burden than surgical-Mohs, strong capital efficiency. The instinct toward Mohs flagship as the "gold standard" is correct on prestige but wrong on risk-adjusted return at GCCP's capital and time-budget envelope.
"No financial model survives a consultant-supply failure."
Master Overview · Section 0 · Three findings
15 · Tier Economics
Capital envelopes, revenue paths, and exit values by tier.
Mid-point figures from the GCCP Dermatology Tier Comparison Model (10-tab Excel). Sensitivity analysis available in the source file.
TIER 1 · €100k–€1m
Sole-consultant chambers
Sessional · 1–2 rooms
Capex
~€0.5m
Y5 Revenue
€1.5m
EBITDA %
22%
Y5 EV
€3.5m
Lowest capital, lowest scaling potential. Defensible only as a network (T1-Net) under a Dublin shared-services hub.
TIER 2 · €500k–€4m
Boutique flagship
Top-scored model · T2-B
Capex
€2.0m
Y5 Revenue
€5.8m
EBITDA %
33%
Y5 EV
€22m
Best risk-adjusted return per the master scoring. EV/Capex 11.0× — highest capital efficiency in the matrix.
TIER 3 · €8m–€50m+
Institutional flagship
Multi-site or Mohs hub
Capex
€15m
Y5 Revenue
€22m
EBITDA %
35%
Y5 EV
€92m
Highest absolute return but highest binding constraint on consultant supply (7–10 consultants). Phase 2/3 progression after T2 proves out.
EV/Capex efficiency by tier · Y5
multiple of invested capital · midpoints
16 · Capex & Unit Economics — Deep Dive
Flagship €17.4m. Satellite €7.4m. Platform IRR 17.5–20% unlevered, 25–29% equity at scale.
Bottom-up unit economics for a flagship Dublin centre, a satellite, and a 3-centre rollout. Triangulated against UK / US listed and PE-disclosed comparators (sk:n, Cadogan, Schweiger, Forefront, Anne Arundel). Source: research/08_capex_opex_unit_economics.md.
Headline platform economics
| Metric | Flagship Dublin (8,000 sq ft) | Satellite (4,000 sq ft) | Platform · 3 centres · 5 yrs |
|---|---|---|---|
| Total all-in capex | €15.5–19.4m | €6.5–8.3m | €29.0–36.5m cumulative |
| Mid-point capex | €17.4m | €7.4m | €32.5m |
| Steady-state revenue (Y3+) | €8.5–10.5m | €4.5–5.5m | €18–22m |
| Steady-state EBITDA margin | 30–34% | 26–30% | 29–32% blended |
| Steady-state EBITDA per centre | €2.7–3.4m | €1.2–1.5m | €5.0–6.3m platform |
| Breakeven revenue per centre | €5.9m | €3.1m | n/a |
| Cash payback (project) | 5.0–5.7 yrs | 5.5–6.2 yrs | n/a |
| Project IRR (unlevered, 10-yr DCF) | 17.5–20.0% | 14.5–17.0% | n/a |
| Equity IRR (60% senior debt, post-SLB exit) | 24–28% | 21–24% | 25–29% platform |
| 10-yr terminal value (8.5× EBITDA mid) | €25–28m | €11–12m | n/a |
Headline call
The unit economics support a multi-billion EBITDA-multiple-grade exit if the flagship clears 80%+ utilisation by Y3 and the consultant fee % stays disciplined at 60–65%. A €17.4m flagship spend produces a €3.0m steady-state EBITDA centre that would be valued at €25–28m on UK healthcare REIT comps alone, before any platform premium. The single largest sensitivity is consultant fee %: a 200 bps shift moves EBITDA margin by c. 4 points and equity IRR by c. 350 bps.
Flagship Dublin · capex breakdown (8,000 sq ft)
Building / shell acquisition + works
| Line | Unit cost | Volume | Low (€000) | High (€000) |
|---|---|---|---|---|
| Shell acquisition (vacant Grade B office, D4) | €600–750/sq ft | 8,000 | 4,800 | 6,000 |
| Stamp duty + acquisition costs | 7.5% | — | 360 | 450 |
| Strip-out and CAT A reinstatement | €55–70/sq ft | 8,000 | 440 | 560 |
| Medical CAT B fit-out (partitions, finishes, joinery) | €275–355/sq ft | 8,000 | 2,200 | 2,840 |
| M&E uplift (HVAC, HEPA, isolated medical earth, UPS) | €180–230/sq ft | 8,000 | 1,440 | 1,840 |
| FF&E (chairs, joinery, signage, art) | — | — | 380 | 470 |
| Sub-total: building | 9,620 | 12,160 | ||
Medical equipment (itemised)
| Equipment | Vendor | Qty | Low (€000) | High (€000) |
|---|---|---|---|---|
| Alex / Nd:YAG laser | Candela GentleMax Pro Plus | 1 | 110 | 150 |
| Picosecond laser | Cynosure PicoSure / Lutronic PicoPlus | 1 | 130 | 170 |
| Q-switched Nd:YAG | Lutronic Spectra | 1 | 80 | 110 |
| CO₂ fractional / ablative | Lumenis UltraPulse / DEKA SmartXide | 1 | 95 | 130 |
| IPL platform | Lumenis M22 / Cynosure Icon | 1 | 60 | 85 |
| Pulsed-dye vascular laser | Candela Vbeam Prima | 1 | 95 | 125 |
| Total body imaging (FotoFinder ATBM) | FotoFinder Systems | 1 | 60 | 85 |
| Hand-held dermoscopes | FotoFinder handyscope / Heine NC2 | 8 | 32 | 48 |
| Electrosurgery | Bovie A1250U / hyfrecator | 3 | 18 | 30 |
| Cryotherapy | CryoPen / Brymill CRY-AC | 2 | 8 | 16 |
| Mohs cryostat | Leica CM1860 / Sakura Tissue-Tek | 1 | 40 | 55 |
| Mohs microscope + bench | Olympus BX46 + grossing station | 1 | 35 | 50 |
| Mohs lab fit-out | Embedding, staining, ventilation | 1 | 60 | 90 |
| Phototherapy cabinet (UVB-NB) | Daavlin / Waldmann | 1 | 45 | 65 |
| PUVA / hand-foot phototherapy | Waldmann | 1 | 18 | 25 |
| Examination chairs / procedure beds | Midmark / Schmitz | 12 | 72 | 108 |
| Sterilisation (autoclave, UWC) | W&H / Melag | 1 | 35 | 50 |
| High-frequency ultrasound | DUB SkinScanner | 1 | 55 | 85 |
| Patch-test station + reagents | Chemotechnique / SmartPractice | 1 | 15 | 22 |
| Sub-total: medical equipment | 1,063 | 1,499 | ||
IT / EMR / digital infrastructure
| Line | Low (€000) | High (€000) |
|---|---|---|
| EMR licence + implementation (HealthOne / Helix / Socrates / ClinicSoftware) | 90 | 140 |
| PACS / image management (FotoFinder Universe) | 55 | 80 |
| Telephony + cloud comms (RingCentral / 8x8) | 25 | 40 |
| Cyber + endpoint protection (Microsoft Defender E5 + Mimecast) | 18 | 28 |
| Patient portal + online booking (Heydoc / Pabau) | 22 | 35 |
| Hardware (laptops, tablets, scanners, printers · 25-user) | 35 | 55 |
| Network / structured cabling (Cat6A + WPA3) | 45 | 65 |
| Sub-total: IT | 290 | 443 |
Soft costs + working capital
| Line | Low (€000) | High (€000) |
|---|---|---|
| Brand identity, photography, web build | 90 | 140 |
| Pre-opening + Y1 launch marketing | 220 | 320 |
| Professional fees (architect, M&E, QS, planning, legal · 10%) | 1,140 | 1,460 |
| Contingency (project · 7.5%) | 850 | 1,090 |
| Working capital reserve (3 months opex) | 700 | 800 |
| Sub-total: soft + WC | 3,000 | 3,810 |
Flagship total · all-in
| Block | Low (€000) | High (€000) | Mid (€000) |
|---|---|---|---|
| Building | 9,620 | 12,160 | 10,890 |
| Medical equipment | 1,063 | 1,499 | 1,281 |
| IT | 290 | 443 | 367 |
| Soft + WC | 3,000 | 3,810 | 3,405 |
| Flagship all-in | 13,973 | 17,912 | 15,943 |
| Per sq ft (all-in) | €1,747 | €2,239 | €1,993 |
| Recommended underwriting target | €15.5–18.5m | €17.0m for IC | |
PropCo / OpCo allocation: PropCo carries shell + stamp + CAT A + structural M&E (~€10.0–12.5m mid); OpCo carries medical CAT B + medical equipment + IT + FF&E + WC (~€5.5–6.0m mid).
Flagship capex composition · midpoint allocation
€15.94m · 8,000 sq ft Dublin flagship
17 · Real Estate Clusters
Six clinical real-estate clusters across the island. Each maps to a distinct tier, brand, and consultant pool.
Site selection follows the consultant-supply and demand-gap evidence — never the inverse. Memos in 03_Real_Estate/ cover Dublin, Cork, Waterford, and Galway in full.
Dublin · 1.1 — D2 / D4 / Ballsbridge corridor
The Harley Street of Dublin. Rents €450–700/sq m; consultant rooms at Pembroke Place command €1,500–2,500/month for half-day sessions. Institute of Dermatologists is the strategic anchor of this cluster — founder-owned, purpose-built. Adare Clinic on Clare Street, Eleanor Higgins, Restorative Dermatology, River Medical, and Eden Medical occupy adjacent blocks.
- Anchor properties: 10 Pembroke Place (IoD, ~2,900 sq ft), Wellington Road, Clare Street, Pembroke Road, Northumberland Road
- GCCP fit: T2-B boutique cosmetic + medical, or T3 flagship (Surgical Institute Dublin sets the precedent)
- Constraint: Direct competition with IoD if positioned as multi-specialty. Differentiate or stay out.
Dublin · 1.2 — Sandyford / Beacon
South-Dublin counterpoint to Ballsbridge. Beacon Medical Group provides infrastructure that few standalones can match — theatre access, imaging, pathology. Cosmetic supply is heavy (Beacon Face & Dermatology, Beacon Consultants Clinic, ClearSkin, ORA).
- Anchor properties: Beacon South Quarter, Beacon consulting suites
- GCCP fit: Sessional rooms within Beacon Hospital ecosystem (lower capex, faster ramp); or boutique medical-derm at perimeter
Dublin · 1.3 — Blackrock / Booterstown
Operationally the densest dermatology venue in ROI — Blackrock Clinic alone hosts 6+ derm consultants (Ryan, Higgins, Coleman, Ormond, Salim, Condon). However the consultants are individually private — there is no single "Blackrock Dermatology" group entity to acquire; you would buy practices one at a time.
Dublin · 1.4 — Hermitage / West Dublin
Lucan / Liffey Valley catchment ≈350k+, materially under-served. Hermitage Medical Clinic runs a light derm offering. This is Dublin's structural whitespace.
- GCCP fit: T2-B or satellite. Lower rent envelope; demand evidence strong (HSE waitlists in West Dublin highest in metro)
Dublin · 1.5 — Mater / D7
Mater Private Network on Eccles St; Skin & Hair Clinic (Aizuri Murad) at Bloom House on the same block; St James's catchment overlap (Ormond). Skin-cancer / Mohs concentration is here.
Cork — College Rd / South Mall + Lee Rd
The only credible secondary-city medical-dermatology cluster. Lee Clinic Dermatology (Lee Road) is the standout independent — Mohs + paediatric capability, €2.5–3.5m revenue, founder-owned, prime acquisition target. Bon Secours College Road runs Ireland's only private Mohs department. UPMC Cork is a new entrant building.
- Anchor properties: Half Moon Street relationship, Princes Street, South Mall, College Road, Lee Road
- GCCP fit: T1 storefront (HALO-fit) on Princes Street; T2 boutique on South Mall; T3 surgical hub adjacent to Bon Secours referral pipeline
- Shell pricing: €460–600/sq ft (Cork city centre)
Galway — Doughiska + Salthill
Galway Clinic at Doughiska (Markham, Shaikh) and Bon Secours Galway run hospital-resident derm models. Perfect Skin (Shaikh's solo practice within Galway Clinic) is an acquisition candidate. Highest-income demographic outside Dublin; MedTech corporate PHI corridor; 15–18 month public derm waits — worst in IE.
- Anchor properties: Doughiska / Galway Clinic adjacency; Salthill / Knocknacarra approach for modern fit-out
- GCCP fit: T2-A medical boutique (HELIX-fit clinical-modern) anchoring biologics + medical derm
- Shell pricing: €420–550/sq ft
Belfast — Lisburn Rd corridor + Stranmillis
Cross-border demand is high — Northern Irish patients already cross the border for private healthcare. Belfast Skin Clinic (Lisburn Rd, multi-specialty), Cathedral Dermatology, Kingsbridge Private Hospital, Ulster Independent Clinic (Stranmillis), Claro Skin Clinic (Kerr's Mohs work), and Marlborough Clinic are the institutional spine. Estimated £25–35m derm-aesthetics combined throughput.
- GCCP fit: Partnership / acquisition with Belfast Skin Clinic likely the most efficient NI entry — already multi-specialty, already founder-led, cross-border patient flow already exists
- Status: Phase 2 in current scope (cross-border / NI regulatory complexity)
Waterford — UPMC Whitfield
Single private hospital in the SE region. UPMC Whitfield (Cork Rd) hosts Rose Clinic; visiting consultants only.
- GCCP fit: T1 satellite from Cork or Dublin · visiting-consultant model · 1,500–3,000 sq ft
City summary table
| City | Indicative footprint | Shell €/sq ft | Status | Stage |
|---|---|---|---|---|
| Dublin | 3,000–8,000 sq ft | €600–750 | Survey complete · 6 sub-clusters mapped | Stage 1 |
| Cork | 2,500–5,000 sq ft | €460–600 | Survey complete · Half Moon St relationship · Lee Clinic acquisition target | Stage 1 |
| Waterford | 1,500–3,000 sq ft | €350–500 | Survey complete · standalone vs. satellite TBD | Stage 1 |
| Galway | 2,500–4,000 sq ft | €420–550 | Survey complete · MedTech corridor | Stage 1 |
| Belfast | 3,000–5,000 sq ft | £500–650 | Acquisition / partnership scoping | Phase 2 |
| Limerick | — | — | Deferred unless surfacing data brings forward | Phase 2 |
PropCo / OpCo structure
GCCP funds and builds medical-grade real estate (PropCo); consultants partner via OpCo equity, analogous to the GCCP hotel operator model. Triple-net lease structure aligns clinical performance with property cashflow without dragging GCCP into clinical operations.
18 · Regulatory Trajectory
HIQA scope is widening. Discipline now is moat later.
Forthcoming Patient Safety (Licensing) Bill 2025 will favour disciplined operators that build to standards before they are required. The window for prudent build-out is open.
| Activity | HIQA registrable today | Trajectory |
|---|---|---|
| Private hospitals (inpatient/day-case surgical derm) | Yes | Status quo |
| Private hospitals (OPD consultant derm) | Yes (Sept 2024) | Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023 |
| Standalone outpatient clinics | Light-touch | Patient Safety (Licensing) Bill 2025 incoming |
| Cosmetic-only nurse/GP-led clinics | Light-touch | Material credential and licensing exposure |
Defensive playbook
- Consultant-led, fellowship-trained across every clinical division — credential transparency is the moat.
- Build to private-hospital infection control and clinical governance standards from day one — not retrofit.
- Insurer participation: dual VHI + ILH; hold Laya at non-participating to preserve M&A optionality.
- Document everything: patient pathways, consent, complications, outcome metrics. The audit trail is the recapitalisation asset.
19 · Exit Thesis
8–12× EBITDA. Validated by UK/EU comparables. No equivalent IE platform yet exists.
August Equity's The Dermatology Partnership (9 clinics, 50+ consultants) was acquired by Bupa Health Services in December 2024 — the clearest validation of the insurer-as-platform model.
| Comparable | Geography | Scale | Multiple | Acquirer / outcome |
|---|---|---|---|---|
| The Dermatology Partnership | UK | 9 clinics, 50+ consultants | undisclosed (8–12×) | Bupa Health Services · Dec 2024 |
| Sk:n Group (TriSpan) | UK | ~95 sites · peak £90–110m | collapse Jul 2024 | Cosmetic-only failure mode |
| Sisu Clinic | IE/UK/US | 24–25 clinics · $20.5m revenue | VC-backed · 47% YoY | Aesthetic-only growth play |
| Laya Healthcare | IE | — | 11× P/E | AXA · €650m · 2023 |
Probable acquirer ranking
- Laya Healthcare (AXA) — 45–55% probability per P4 verified. Explicit margin-recapture mandate. Hold non-participating to preserve optionality.
- UK platform consolidator (Bupa, post-Dermatology-Partnership integration; or PE-backed UK derm rollup) — 25–35%.
- Pan-European healthcare PE (CVC, EQT, Apax mid-market) — 15–25%.
- VHI / ILH (state-linked) — <10%; structural acquirer of last resort.
Exit target window
Years 5–7 from Stage 1 capital deployment. Recapitalisation-attractive once two operating centres are at maturity (€20–30m run-rate revenue, 25–35% EBITDA margin) with Phase 2 surgical centre in development.
20 · Decision Log
What we've decided. Why. When.
Canonical record of strategic decisions on the dermatology thesis. Source: 08_Decision_Log/decisions.md.
| Date | Decision | Rationale |
|---|---|---|
| 2026-04-25 | Geographic scope locked to four cities (Dublin, Cork, Waterford, Galway). | Limerick / Belfast deferred to Phase 2 — surfacing data does not yet justify Stage 1 inclusion. |
| 2026-04-25 | Cork no longer presumed Clinic 1. | Site selection is data-led, not partner-proximity-led. Half Moon Street narrative is one signal among several; must compete with the other three cities on evidence. |
| 2026-04-25 | Tier 2 boutique (T2) is the working primary model. | Top-scored cell on the 9-cell matrix (78.4 / 100); EV/Capex 11.0× highest in matrix; capital envelope fits a 2-3 centre platform thesis. |
| 2026-05-01 | Hold Laya at non-participating provider status. | Preserve M&A optionality. AXA's 2023 acquisition of Laya was explicit margin-recapture; becoming a fee-capped Laya provider destroys exit value. |
| 2026-05-07 | Cosmetic-only Tier D model rejected as GCCP path. | Sk:n collapse July 2024 illustrates the structural fragility. Credential transparency is the moat against Therapie/Sisu — not price. |
21 · Open Questions
What we still need to resolve before IC-grade conviction.
Source: 08_Decision_Log/open_questions.md. These five questions block IC presentation; each has an owner and a target resolution path.
| # | Question | Why it matters | Path to resolution |
|---|---|---|---|
| Q1 | Which clinical partner anchors Clinic 1? | No financial model survives consultant-supply failure. The first consultant must be locked before site closes. | Direct outreach · Type B holders · 6–8 named candidates |
| Q2 | Which property type for Clinic 1 (boutique medical-led vs. cosmetic-led)? | Drives capex envelope (€1.8m vs. €2.0m), revenue mix, and consultant brief. | Site shortlist + consultant brief alignment by Q3 2026 |
| Q3 | Product strategy — own retail brand vs. partner SkinCeuticals/ZO? | 15–25% of Y5 revenue at 50–65% gross. ID Formulas (Q1 2026 launch) is the IE precedent. | Decision deferrable to Y2; not gating Stage 1 |
| Q4 | Cork vs. Galway — which city for Clinic 1? | Different anchor logic: surgical anchor → Cork (Bon Secours pipeline); recurring medical anchor → Galway (cleaner unit econ + worst public waits). | P5 county heatmap + consultant availability data + IC discussion |
| Q5 | OpCo equity % for clinical partners? | Recruitment competitiveness vs. dilution discipline. | Term-sheet drafting · benchmark vs. UK platform comparables |
Grand Canal Capital Partners | Confidential | Internal Only
Source-of-truth: GCCP_REPOS/GCCP Dermatology MASTER/ · Companion: Master Overview Deck